此次发行前，公司无控股股东、实控人。发行完成后，海鲸药业将持有公司20%股份。同时，此次发行 后，公司董事会设置9名董事，其中3名独立董事，海鲸药业将向公司董事会提名5名董事，超过董事半 数。海鲸药业成为公司控股股东，自然人张现涛将成为公司实控人。 人民财讯9月22日电，盟科药业(688373)9月22日公告，公司拟向南京海鲸药业股份有限公司(简称"海鲸 药业")发行股票募资不超过10.33亿元(含)，扣除发行费用后全部用于公司日常研发与经营投入。 ...

盟科药业公告，公司为进一步增强公司综合竞争力，根据公司发展需要，拟向特定对象发行A股股票募 集资金总额不超过103,257.86万元，扣除发行费用后，实际募集资金将全部用于公司日常研发与经营投 入。本次发行完成后，公司控股股东将变更为海鲸药业，自然人张现涛将成为公司实际控制人。 ...

格隆汇9月22日丨中京电子(002579.SZ)公布，拟向特定对象发行股票的募集资金总额不超过70,000.00万 元，扣除发行费用后募集资金将全部用于泰国PCB智能化生产基地项目、惠州中京产线技改与升级项 目、补充流动资金。本次发行的发行对象为不超过35名（含本数）符合中国证监会规定条件的特定对 象，其中，公司实际控制人杨林拟认购金额不低于0.7亿元（含本数）且拟认购股票总数不超过本次向 特定对象发行股票总股数的30%（含本数）。 ...

本次向特定对象发行募集资金总额为不超过7亿元(含本数)，在扣除相关发行费用后将全部用于泰国 PCB智能化生产基地项目、惠州中京产线技改与升级项目及补充流动资金。 中京电子(002579.SZ)披露2025年度向特定对象发行A股股票预案，公司拟向不超过35名(含本数)特定对 象发行股票，其中，公司实际控制人杨林拟认购金额不低于0.7亿元(含本数)且拟认购股票总数不超过本 次向特定对象发行股票总股数的30%(含本数)。发行价格不低于定价基准日前20个交易日公司股票交易 均价的80%。本次向特定对象发行股票的数量为不超过发行前公司总股本的30%。 MACD金叉信号形成，这些股涨势不错！ ...

中京电子（002579）(002579.SZ)披露2025年度向特定对象发行A股股票预案，公司拟向不超过35名(含 本数)特定对象发行股票，其中，公司实际控制人杨林拟认购金额不低于0.7亿元(含本数)且拟认购股票 总数不超过本次向特定对象发行股票总股数的30%(含本数)。发行价格不低于定价基准日前20个交易日 公司股票交易均价的80%。本次向特定对象发行股票的数量为不超过发行前公司总股本的30%。 本次向特定对象发行募集资金总额为不超过7亿元(含本数)，在扣除相关发行费用后将全部用于泰国 PCB智能化生产基地项目、惠州中京产线技改与升级项目及补充流动资金。 ...

人民财讯9月22日电，贵研铂业（600459）9月22日公告，公司拟向特定对象发行A股股票，募资不超过 12.91亿元(含)，投资于科技创新平台类项目、产业转型升级类项目以及补充流动资金。 ...

2024年7月，公司控股股东变更为长江一号产投，实际控制人调整为湖北省国资委全资控股的长江产业 投资集团有限公司，企业控制权实现国有化转轨。公司近年资产负债率有所波动，2022年末、2023年末 及2024年末分别为53.64%、55.65%和53.29%，至2025年6月末已降至49.48%。 南方财经9月22日电，奥特佳(002239.SZ)于9月19日公告，拟调整2025年度向特定对象发行A股股票方 案。原方案拟募集资金总额不超过5.9亿元，发行股票数量上限不超过2.3228亿股；调整后募资总额降至 不超过4.9965亿元，发行数量上限缩减至不超过1.9671亿股。调整原因为前次募集资金中用于补充流动 资金的部分超过总额30%，超出部分需从本次募资中扣除，调整后募集资金仍将全部用于补充流动资金 或偿还银行贷款。 本次定增发行对象为公司控股股东湖北长江一号产业投资合伙企业（有限合伙），其将以现金方式全额 认购，发行价格为2.54元/股，限售期为18个月。该定增事宜已获董事会和股东大会审议通过，尚需经 深圳证券交易所审核通过及中国证监会同意注册后方可实施。 ...

Core Viewpoint - The significant stock price increase of Yokogawa Precision is attributed to strong performance in earnings, a successful private placement, and robust growth in the automotive lightweight interior parts business [1] Group 1: Financial Performance - In the first half of 2025, the company reported a revenue growth of 34.15% and a net profit increase of 79.04%, with a non-recurring net profit growth of 86.7%, indicating a substantial improvement in financial performance [1] - The company completed a private placement of 588 million yuan at an 18.11% premium, with subscriptions from 11 institutions including Caifeng Fund, reflecting strong institutional confidence in the company [1] Group 2: Automotive Business Growth - The automotive lightweight interior parts business experienced a remarkable revenue growth of 124%, with a gross margin increase of 5.53 percentage points, aligning with the industry's trend towards lightweight vehicles, particularly in the electric vehicle sector [1] - The automotive parts sector saw multiple stocks performing actively on September 22, 2025, creating a sector-wide momentum effect [1] Group 3: Market Dynamics - On the day of the stock surge, there was a net inflow of large orders, indicating strong institutional buying interest, which contributed to the stock's price increase [1] - The stock broke through short-term moving average resistance levels, indicating a strengthening trend and attracting further investor attention [1]

Core Viewpoint - The investor raises concerns about the potential risks associated with the company's past private placements, suggesting that the introduction of certain investors may not be beneficial for long-term shareholders [1] Group 1: Investor Concerns - The investor highlights vulnerabilities in previous private placements, indicating that they may have diluted the interests of long-term shareholders [1] - The introduction of Huaneng and Yuneng is compared to "close relatives marrying," implying a lack of diversity in investor backgrounds [1] - The involvement of three investment companies from Shandong is viewed as potentially harmful, as Shandong hosts two of the largest electrolytic aluminum producers in the country [1] Group 2: Company Response - The company acknowledges the investor's concerns and expresses gratitude for the feedback [1]

Group 1 - Jinbo Bio has received approval from the Beijing Stock Exchange for a targeted stock issuance, with a maximum of 7.1757 million shares to be issued, aiming to raise up to 2 billion yuan [1][2] - The strategic investor for this issuance is Yangshengtang, which will acquire shares at a price of 278.72 yuan per share, resulting in a 6.24% ownership stake in Jinbo Bio post-issuance [2] - The funds raised will be allocated as follows: 1.15 billion yuan for the development of a humanized collagen FAST database and product development platform, and 850 million yuan for working capital [2] Group 2 - The collaboration with Yangshengtang is expected to enhance Jinbo Bio's core competitiveness and innovation capabilities, as well as improve market expansion and sales performance [3] - In addition to Jinbo Bio's targeted stock issuance, Wantong Hydraulic has also received approval for a targeted convertible bond issuance, with a maximum of 1.5 billion yuan to be raised [4] - Wantong Hydraulic's convertible bonds will be used entirely for working capital, addressing the company's funding needs and enhancing its competitive strength in the hydraulic sector [5]